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Background: Pneumatosis intestinalis (PI) is defined as the presence of gas in the bowel wall and is a relatively rare
finding. PI has been associated with various pathological conditions and medications. Although several chemotherapeutic
agents and molecular targeted therapy agents are reported to be associated with PI, there have been few reports
describing the association between the anti-epidermal growth factor receptor agent gefitinib, a tyrosine kinase
inhibitor (TKI), and PI. The present report describes a case of PI secondary to gefitinib therapy.
Case presentation: An 80-year-old woman who had been diagnosed with recurrent lung adenocarcinoma
presented with remarkable appetite loss, abdominal distension, and constipation after starting gefitinib therapy.
A computed tomography (CT) scan of the abdomen revealed PI extending from the small intestine to the rectum. The
patient was managed conservatively, and gefitinib therapy was discontinued. Subsequently, the symptoms improved
and a follow-up abdominal X-ray showed a reduction in intramural air. After gefitinib was restarted, PI occurred three
more times.
Conclusions: Although PI is extremely rare, physicians should be aware of the risk of PI in patients undergoing gefitinib
therapy.Background
Pneumatosis intestinalis (PI) is relatively rare finding
characterized by the presence of gas within the intestinal
wall. This can be caused by bowel ischemia, mechanical
trauma, inflammatory disease, autoimmune disease,
intestinal neoplasm, obstructive pulmonary disease,
thromboembolism, or several medications [1–3]. Re-
cently, molecular-targeted drugs have been shown to
cause gastrointestinal toxicity, including PI perforation,
enteritis, and fistula formation [1, 4–6]. Anti-epidermal
growth factor receptors such as cetuximab and erlotinib
have been reported to be associated with PI; however, only
a few cases have been reported in association with
gefitinib treatment [1, 7–9]. This is a report of PI asso-
ciated with gefitinib therapy.* Correspondence: amaeda@med.kawasaki-m.ac.jp
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An 80-year-old female patient with recurrent lung cancer
was admitted to our hospital because of anorexia, abdom-
inal distension, and constipation. She had been diagnosed
with recurrent left lung cancer with multiple bone metasta-
ses. She had been treated with oral gefitinib for about
6 weeks, which appeared to stabilize the disease. Her past
medical history included rheumatoid arthritis (RA), cor
pulmonale, bronchial asthma, and hypothyroidism, which
were all under medical control. She was receiving prednis-
olone (PSL, 10 mg/day) for RA treatment. An abdominal
X-ray showed an abnormal intestinal gas shadow (Fig. 1),
and computed tomography (CT) revealed intestinal dila-
tion with diffuse thickening of practically the entire intes-
tinal wall, intramural gas, and intraperitoneal free air,
indicating PI (Fig. 2). We selected conservative treatment
with I.V. antibiotics because the increase in inflammatory
parameters in the blood samples was mild (white blood cell
(WBC), 8430/μL; C-reactive protein (CRP), 7.11 mg/dL;
pH, 7.337; and lactate, 0.87 mEq/L) and no signs of sepsis,
free gas near the portal vein, or bowel perforation werele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Abdominal X-ray performed before treatment revealed intestinal
dilation and intraluminal gas
Fig. 2 A coronal CT scan of the abdomen showed severe PI and
subcutaneous emphysema (white arrow). Gas tracking wall is visualized
parallel to the intestinal mucosa
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cluding gefitinib.
We speculated that this patient’s PI was induced by PSL
therapy; however, it was not possible to decrease the
amount of PSL because of RA. The symptoms gradually
improved, and a follow-up abdominal X-ray revealed
decreased intramural air (Fig. 3). Considering the good re-
sponse of lung cancer to gefitinib, the drug was restarted;
however, within 2 weeks of gefitinib re-initiation, the
patient redeveloped marked abdominal distention, and
extensive pneumatosis led to drug cessation.
The same episode occurred three times during gefi-
tinib therapy. We discontinued the administration of
gefitinib after PI recurred the third time and the patient
did not experience further episodes after discontinuing
the drug.
Discussion
PI is a condition of extraluminal gas predominantly
localized to the submucosal and subserosal planes of the
intestine, but it can also be found in the muscularis
propria.
Multiple theories exist for the cause of PI onset. Three
different possibilities for the source of gas within the
intestinal wall have been considered, including intraluminal
gas, pulmonary gas, and gas produced by bacteria. Mucosal
damage, increased intraluminal pressure, or both contribute
to PI. Mucosal damage may result from inflammation, a de-
fect in the gut barrier function, and steroid- or molecular-
targeted therapy. Many PI-associated conditions have beenFig. 3 Abdominal X-ray performed after treatment revealed decreased
intraluminal gas
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causative factor. It has been suggested that long-term ad-
ministration of corticosteroids induces atrophy of the
intestinal mucosa, which sometimes results in a mucosal
defect and subsequent translocation of gas into the sub-
mucosal layer [10–12]. We initially speculated that PSL
treatment was the cause of PI. However, considering the
fact PI recurred after the initiation of gefitinib therapy, we
concluded that gefitinib therapy led to PI, although the
underlying mechanism is not well understood.
Several recent reports have suggested that PI is associated
with molecular targeted therapy agents such as vascular
endothelial growth factor (VEGF) inhibitors, tyrosine kinase
inhibitors (TKI), mammalian target of rapamycin (mTOR)
inhibitors, and immune modulators [1]. Molecular-targeted
therapies can be beneficial for treating cancers but can
often induce severe bowel toxicity. This effect is particularly
true with VEGF inhibitors such as bevacizumab, which has
been shown to increase the risk of perforation. It has been
hypothesized that the decreased blood supply caused by
angiogenesis inhibition may reduce the capillary density of
intestinal villi, possibly causing abdominal hypoxia and
microperforation and allowing air to infiltrate the bowel
wall [1, 5].
In general, gefitinib has a good toxicity profile among
the targeted molecular therapy agents. However, some
patients develop specific and severe toxicities because
these molecular targets also affect normal cells. Although
gefitinib is generally well tolerated, its most commonly
reported toxicities concern the gastrointestinal tract (diar-
rhea, nausea, and vomiting) and skin (rash, acne, dry skin,
and pruritus). Severe gastrointestinal toxicity caused by
gefitinib is uncommon, and only 1 % of patients receiving
gefitinib therapy develop grade 3 or 4 diarrhea [9, 13]. To
the best of our knowledge, only a few studies, including
the current case report, have reported the association
between PI and gefitinib [8, 9].
Most cases of PI are asymptomatic or mild; however,
in the present case, the patient’s symptoms were anorexia
and abdominal distension. Patients with PI most frequently
present with vomiting, abdominal distension, and abdom-
inal discomfort [14]. These diagnoses are made radiograph-
ically and not by symptoms. Conservative management is
preferable; however, in cases involving elevated CRP or
WBC levels as well as signs of sepsis, bowel perforation, or
free gas near the portal vein, immediate surgery is indicated
[13–16]. In this case, the patient’s CRP levels remained at
higher than normal levels on account of RA. Because we
did not observe intestinal perforation or an increase in
WBC levels, we selected conservative treatment.
Conclusions
This is a rare case report of PI caused by gefitinib. The
symptoms of PI appear to be minor; however, thiscondition has the potential to lead to intestinal perfor-
ation. Although this complication is extremely rare,
physicians should be aware of the risk of PI in patients
undergoing gefitinib therapy.
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